Learn how to find the current needed to deflect a compass needle in this step-by-step physics tutorial! Explore the principles of magnetic fields, current-carrying wires, and the interaction with a ...

Furthering your education locally is easy, with a wide range of training opportunities offered by schools and organisations island-wide.

Psychedelic drug developer Compass Pathways is preparing to talk to the FDA about filing its psilocybin therapy COMP360 for approval in treatment-resistant depression (TRD), after reporting positive ...

New Compass program pays listing agents a 10% fee for referring buyer inquiries from their listings to colleagues.

The Brookfield-owned hyperscale developer is planning to issue asset-backed securities backed by six new, fully leased data centers in Phoenix and Toronto, according to a presale report from Moody’s ...

The American Depositary Shares ("ADS") of the United Kingdom-based biotech Compass Pathways plc (CMPS) are soaring today, after management announced its psychedelic drug candidate COMP006 had met the ...

Compass’ fourth-quarter earnings call this week came with more than bottom-line metrics.  The company announced a three-year partnership with Rocket and Redfin. The “strategic alliance,” as Compass ...

The FDA outright refuses to review Moderna’s mRNA-based flu vaccine as CBER director Vinay Prasad’s conduct is scrutinized; Disc Medicine receives an unexpected rejection, which Prasad may also have ...

Elaine Chen covers biotech, co-writes The Readout newsletter, and co-hosts STAT’s weekly biotech podcast, The Readout Loud. You can reach Elaine on Signal at elaineywchen.70. Good morning. I’ve fallen ...

Rocket Pro adds Pro Purchase Power, offering 40 bps more with Compass buyer agents, and launches Jupiter loan origination system.

Compass Pathways plc (Nasdaq: CMPS), a biotechnology company dedicated to accelerating patient access to evidence-based innovation, announced that tomorrow it will report new clinical data from two ...

Investing.com - Canaccord Genuity raised its price target on Compass Therapeutics (NASDAQ:CMPX) to $13.00 from $10.00 on Wednesday, while maintaining a Buy rating on the stock. The new target ...